Galera to Present at Three Upcoming Investor Conferences in September

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/22/2026

1. WMT
2. ROST
3. AAP
4. NVDA
5. SPY

6. AVGO
7. SPCX
8. BABA
9. OSIS
10. REAX

Get Alerts GRTX Hot Sheet

Price: $0.15 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at three upcoming virtual investor conferences in September.

Presentation Details:

Event: H.C. Wainwright 23rd Annual Global Investment ConferenceDate: Monday, September 13, 2021 Time: On-demand beginning at 7:00 a.m. ET

Event: Oppenheimer Fall Healthcare Life Sciences & MedTech SummitDate: Tuesday, September 21, 2021 Time: 11:35 a.m. ET

Event: Cantor Fitzgerald Global Healthcare ConferenceDate: Wednesday, September 29, 2021 Time: 10:00 a.m. ET

Live webcasts from the three presentations will be accessible from the Investors page of Galera’s website, investors.galeratx.com. Following the events, archived webcasts will be available on the Galera website for 30 days.

About Galera Therapeutics

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (avasopasem, or GC4419), a selective small molecule dismutase mimetic in late-stage development to reduce the incidence and severity of radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer. Avasopasem is also in development for radiotherapy-induced esophagitis in patients with lung cancer. Avasopasem has been granted FDA Fast Track and Breakthrough Therapy designations for the reduction of SOM induced by radiotherapy, with or without systemic therapy. Galera’s second dismutase mimetic product candidate, GC4711, is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.

Investor Contacts:Christopher DegnanGalera Therapeutics, Inc.610-725-1500[email protected]

William WindhamSolebury Trout646-378-2946[email protected]

Media Contact:Zara LockshinSolebury Trout646-378-2960[email protected]